• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.13% Nasdaq Up0.70%

    More On EVT.DE

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials


    Evotec AG (EVT.DE)

    -XETRA
    3.68 Down 0.03(0.78%) Dec 23, 11:35AM EST
    Add to Portfolio
    ProfileGet Profile for:
    Evotec AG
    Manfred Eigen Campus
    Essener Bogen 7
    Hamburg, 22419
    Germany - Map
    Phone: 49 4056 0810
    Fax: 49 405 608 1222
    Website: http://www.evotec.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drugs - Generic
    Full Time Employees:718

    Business Summary 

    Evotec AG, together with its subsidiaries, provides drug discovery solutions for pharmaceutical and biotechnology companies, and academic institutions worldwide. Its services comprise target ID and validation, hit identification, compound management, chemistry, ADME (absorption, distribution, metabolism and excretion) profiling, proteomics, reagent production, in vitro pharmacology, in vivo pharmacology, and integrated services. The company has various products under clinical stage comprising DiaPep277 for diabetes type 1; EVT3021 for Alzheimer's disease; EVT201 for insomnia; Somatoprim for Acromegaly; EVT1032 for TRD; EVT401 inflammation; and ND³ for oncology. It also has various pre-clinical stage products, including ND³ for pain and oncology; endometriosis products; and EVT770 for diabetes type 2/1, as well as discovery stage products comprising EVT070 for diabetes type 2; and various products for inflammation, diabetes type 2, diabetes type 2/1, kidney disease, and Alzheimer’s disease. The company has alliances and partnerships with various companies comprising AstraZeneca AB, Bayer Pharma AG, Boehringer Ingelheim Pharma GmbH & Co. KG, CHDI Foundation, Inc., MedImmune, LLC/AstraZeneca PLC, Genentech, Inc., the Jain Foundation, Janssen Pharmaceuticals, Inc., Johnson & Johnson Innovation, Ono Pharmaceutical Co., Ltd., UCB Pharma, and Fraunhofer Institute for Molecular Biology and Applied Ecology; and collaboration with Eternygen GmbH. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Evotec AG

    Key Executives 
     PayExercised
    Dr. Werner Lanthaler MBA,MPA, 45
    Chief Exec. Officer
    601.00KN/A
    Mr. Colin Bond , 53
    Chief Financial Officer and Member of the Management Board
    360.00KN/A
    Dr. Mario Polywka Ph.D., 52
    Chief Operating Officer and Member of the Management Board
    409.00KN/A
    Dr. Cord Dohrmann Ph.D.,
    Chief Scientific Officer and Member of the Management Board
    372.00KN/A
    Katja Schrader ,
    Chief Editor
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in EUR.